Kevin J. Harrington

Kevin J. Harrington, MBBS, PhD, FRCP, FRCR is Professor of Biological Cancer Therapies at The Institute of Cancer Research (ICR) and Honorary Consultant Clinical Oncologist at The Royal Marsden Hospital in London. He is an internationally recognized leader in the development of oncolytic virus immunotherapy and the combination of radiotherapy with novel immune agents for head and neck cancer. Dr. Harrington played a central role in early-phase clinical development of talimogene laherparepvec (T-VEC), the first oncolytic virus to receive regulatory approval, and has led studies investigating T-VEC combinations with pembrolizumab and radiotherapy in HNSCC. He was a key investigator in KEYSTONE-001, a phase Ib trial demonstrating the safety and activity of pembrolizumab in previously treated HNSCC, contributing to early proof-of-concept for checkpoint inhibition in this disease. Dr. Harrington has pioneered the concept that radiotherapy serves as an in situ vaccine, augmenting immune responses to tumors, and has designed clinical trials testing this hypothesis in HNSCC and other solid tumors. He has published over 250 peer-reviewed papers and holds several patent applications in the field of oncolytic virotherapy.